Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Moon memorial: Artemis 2 astronauts name lunar 'bright spot' after mission commander's late wife - 2Deadly attack on kindergarten reported in Sudan
- 3Novartis eyes more bolt-on acquisitions, CEO says
- 4Embrace Effortlessness: Moderation and Cleaning up Tips
- 5Germany's Bundestag extends two armed forces missions abroad
- Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- The many ways that baking is winter therapy. With a delicious ending
- A whale stranded at a Baltic Sea resort has swum off a sandbank. But it isn't safe yet
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- German men need approval for stays abroad under military service law
- Bad flu season getting worse; skyrocketing cases set state record
- Gaza humanitarian efforts reach key milestone as UNICEF vaccinates some 13,000 children
- Netanyahu leads meeting on West Bank riots, Katz defends axing administrative detention for Jews
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
